BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 19930185)

  • 1. Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions.
    Felfly H; Trudel M
    Br J Haematol; 2010 Feb; 148(4):646-58. PubMed ID: 19930185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term correction of beta-thalassemia with minimal cellular requirement and transplantation modalities.
    Felfly H; Trudel M
    Mol Ther; 2007 Sep; 15(9):1701-9. PubMed ID: 17519891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
    Shizuru JA; Jerabek L; Edwards CT; Weissman IL
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte colony-stimulating factor prior to nonmyeloablative irradiation decreases murine host hematopoietic stem cell function and increases engraftment of donor marrow cells.
    Barese C; Pech N; Dirscherl S; Meyers JL; Sinn AL; Yoder MC; Goebel WS; Dinauer MC
    Stem Cells; 2007 Jun; 25(6):1578-85. PubMed ID: 17347493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine and math models for the level of stable mixed chimerism to cure beta-thalassemia by nonmyeloablative bone marrow transplantation.
    Roberts C; Kean L; Archer D; Balkan C; Hsu LL
    Ann N Y Acad Sci; 2005; 1054():423-8. PubMed ID: 16339691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. W/Wv marrow stromal cells engraft and enhance early erythropoietic progenitors in unconditioned Sl/Sld murine recipients.
    Bubnic SJ; Wang XH; Clark BR; Keating A
    Bone Marrow Transplant; 2002 Dec; 30(12):867-72. PubMed ID: 12476278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
    Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
    Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
    Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
    Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic correction of sickle cell disease: insights using transgenic mouse models.
    Blouin MJ; Beauchemin H; Wright A; De Paepe M; Sorette M; Bleau AM; Nakamoto B; Ou CN; Stamatoyannopoulos G; Trudel M
    Nat Med; 2000 Feb; 6(2):177-82. PubMed ID: 10655106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells.
    Luck L; Zeng L; Hiti AL; Weinberg KI; Malik P
    Exp Hematol; 2004 May; 32(5):483-93. PubMed ID: 15145217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cells: potential new applications for translational medicine.
    Felfly H; Haddad GG
    J Stem Cells; 2014; 9(3):163-97. PubMed ID: 25157450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
    Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice.
    Down JD; Westerhof GR; Boudewijn A; Setroikromo R; Ploemacher RE
    Bone Marrow Transplant; 1998 Feb; 21(4):327-30. PubMed ID: 9509964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras.
    Taniguchi H; Abe M; Shirai T; Fukao K; Nakauchi H
    J Immunol; 1995 Dec; 155(12):5631-6. PubMed ID: 7499847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.